Foundational guide
Cagrilintide Dosage Chart: Tier One Data, Single Source
Forty-five registered studies, twenty-two in Phase 3, and one lead sponsor on every entry. The evidence is strong and it has not been independently reproduced.
Cagrilintide is the strongest commercial evidence position examined on this site, and it illustrates something the grading method has to handle carefully: trial quality and independence are separate axes, and a record can score at the top of one while scoring nothing at all on the other.
The programme, by phase
| Phase | Studies | Independent entries |
|---|---|---|
| Phase 3 | 22 | 0 |
| Phase 1 | 17 | 0 |
| Phase 2 | 6 | 0 |
Roughly 25 of the 45 are recorded as completed. Novo Nordisk is lead sponsor on every entry, which is unremarkable during development and is still the single most important qualifier on any figure drawn from the programme.
Two axes, graded separately
On trial quality the record is tier one: controlled, prespecified, late stage, at scale. On independence it scores zero, because no group outside the sponsor has run a study. Reporting only the first produces an overstatement; reporting only the second produces a dismissal. Both are wrong.
A third axis is authorisation, and it is not evidence at all. No regulator has approved the compound, so no labelled quantity exists. A cagrilintide dosage chart restates protocol quantities, which is legitimate when labelled as such and misleading when presented as a dose.
The partner drug is part of the measurement
The registered programme studies cagrilintide alongside semaglutide. A quantity from a combination protocol is a property of that combination, not of the molecule in isolation, because exposure, tolerability and titration were all set with the partner in view.
Carrying such a figure to a different partner agent changes mechanism, half-life and schedule simultaneously. That is three variables moving at once, and no registered study measured the result.
Frequently asked questions
- What evidence tier does cagrilintide reach?
- Tier one. Controlled human trials with prespecified endpoints exist in large numbers, including 22 registered Phase 3 studies, roughly 25 of the 45 recorded as completed.
- Does a single sponsor lower the tier?
- It does not lower the tier of an individual well-conducted trial, but it means the body of evidence has not been independently reproduced, which is a separate axis from trial quality.
- Is there an authorised quantity?
- No. Authorisation requires a regulator to approve a label, and that has not occurred. Trial quantities and authorised doses are different objects.
- Do figures transfer between combination partners?
- No. The registered programme pairs cagrilintide with semaglutide. A different partner changes mechanism, half-life and titration schedule, so a quantity established alongside one does not describe the other.
- How does this compare with the rest of this site?
- It is the strongest commercial evidence position examined here. Most compounds covered have zero registered trials or a single record of doubtful provenance.
Limitations of the evidence
This page grades evidence and prints no administration guidance. Cagrilintide holds no marketing authorisation in any market, so no authorised quantity exists despite a large late-stage programme. Every registered study lists a single commercial sponsor and no independent replication appears in the registry. The registered programme pairs the compound with semaglutide; quantities from that pairing carry no read-across to a combination with any other agent. Nothing here describes or recommends human use.